[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pleural-neoplasm\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pleural-neoplasm":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,44],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":5},"100490898","phase-2-phase-ii-trial-of-lung-chemoemobolization-100490898",false,"NCT05672108","Phase II Trial of Lung Chemoemobolization","Inclusion Criteria:\n\n* Lung cancer or lung metastases, with lung, endobronchial, pleural, or mediastinal tumors that are progressing on systemic therapy (or the patient cannot tolerate systemic therapy), and that are not amenable to resection, thermal ablation, or ablative radiation therapy\n* Lung-dominant disease (majority of active tumor volume is in the chest)\n* At least 18 years old\n\nExclusion Criteria:\n\n* Eastern Cooperative Oncology Group (ECOG) performance status \\> 2\n* Oxygen saturation \\< 92% on room air\n* Forced expiratory volume in 1 second (FEV1) \\< 60%\n* No measurable treatable disease, per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 (for example, unable to measure tumor size on CT, or lung nodules are all \\< 1 cm)\n* Life expectancy \\< 6 months\n* Pulmonary hypertension (diagnosed or suspected on echocardiography, CT, magnetic resonance imaging \\[MRI\\], or direct pressure measurement)\n* Recent pulmonary embolism (within 3 months)\n* Pulmonary arteriovenous malformation\n* Active lung infection (pneumonia, empyema, or lung abscess requiring therapy within 1 month)\n* Symptomatic heart failure (American College of Cardiology \\[ACC\\]\u002FAmerican Heart Association \\[AHA\\] stage C or D)\n* Left bundle branch block (contraindication to pulmonary angiography)\n* Renal failure (estimated glomerular filtration rate \\[eGFR\\] \\< 30 mL\u002Fmin\u002F1.73 m\\^2)\n* Pregnancy or intent to become pregnant\n* Breast feeding\n* Altered mental status that would interfere with consent or follow-up\n* Platelets \\< 50,000 (after transfusion, if needed)\n* International normalized ratio (INR) \\> 2 (after transfusion, if needed)\n* Hemoglobin \\< 7 (after transfusion, if needed)\n* Hyperthyroidism or history of hyperthyroidism, including subclinical hyperthyroidism (contraindication to lipiodol)\n* Planned radioactive iodine imaging or therapy (contraindication to lipiodol)\n* Allergy to lipiodol or mitomycin\n* Allergy to iodinated contrast that cannot be treated with steroid \u002F diphenhydramine premedication\n* Any condition that, in the opinion of the investigator, would interfere with evaluation of the investigational product, or that would affect subject safety","ALL","18 Years",{"count":18,"type":19},30,"ESTIMATED","INTERVENTIONAL",[22],"PHASE2","This phase II trial evaluates how well transarterial chemoembolization (TACE) works for treating patients with non-small cell lung cancer or lung metastases. TACE is a minimally invasive procedure that involves injecting chemotherapy directly into an artery that supplies blood to tumors, and then blocking off the blood supply to the tumors. Mitomycin (chemotherapy), Lipiodol (drug carrier), and Embospheres (small plastic beads that block off the artery) are injected into the tumor-feeding artery. This traps the chemotherapy inside the tumor and also cuts off the tumor\\'s blood supply. As a result, the tumor is exposed to a high dose of chemotherapy, and is also deprived of nutrients and oxygen. TACE can be effective at controlling or stopping the growth of lung tumors.",[25,26,27,28,29,30,31],"Lung Non-Small Cell Carcinoma","Mediastinal Neoplasm","Pleural Neoplasm","Lung Metastases From Any Primary","Endobronchial Metastases","Colon Cancer","Sarcoma","RECRUITING","2026-03-03",{"date":35,"type":36},"2026-03-05","ACTUAL",{"date":38,"type":36},"2023-05-12",{"date":40,"type":19},"2027-10-28",{"name":42,"class":43},"City of Hope Medical Center","OTHER",{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":54,"conditions":55,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":56,"startDateStruct":57,"completionDateStruct":59,"leadSponsor":61,"locationsCount":63},"100321508","indwelling-pleural-catheters-with-or-without-doxycycline-in-treating-patients-with-malignant-pleural-effusions-100321508","NCT03465774","Indwelling Pleural Catheters With or Without Doxycycline in Treating Patients With Malignant Pleural Effusions","A Prospective Observational Cohort Study of Indwelling Pleural Catheters Versus Indwelling Pleural Catheters Plus Doxycycline Pleurodesis for Treatment of Malignant Pleural Effusions","Inclusion Criteria:\n\n* Outpatients with MPE undergoing IPC placement\n* Sufficient mental capacity to provide informed consent and answer Short-Form Six-Dimension health index (SF-6D) and Borg score questions\n* Inpatients that are expected to be discharged within 5 days of receiving an indwelling pleural catheter\n\nExclusion Criteria:\n\n* Patients undergoing pleurodesis for benign disease (e.g., spontaneous pneumothorax)\n* Inability or unwillingness to give informed consent\n* Inability to perform phone call and clinical follow-up at MD Anderson Cancer Center (MDACC)\n* Pregnancy\n* Previous intrapleural therapy for MPE on the same side\n* Eastern Cooperative Oncology Group (ECOG) of 4 and life expectancy =\\\u003C 2 weeks\n* Doxycycline allergy\n* Extensive loculations or hydropneumothorax or other contraindication to pleurodesis\n* Chylous effusions associated with malignant disease",{"count":52,"type":19},208,"OBSERVATIONAL","This study is designed to obtain preliminary data comparing indwelling pleural catheters (IPCs) versus IPCs plus doxycycline for pleurodesis as treatments for malignant pleural effusion (MPE). Indwelling pleural catheters (IPCs) are commonly used to treat pleural effusions (build-up of fluid in the lungs). Doxycycline is an antibiotic that is also used to treat pleural effusions. The goal of this clinical research study is to learn if adding doxycycline to the use of an IPC can lead to shorter treatment times with IPCs.",[27],{"date":35,"type":36},{"date":58,"type":36},"2018-03-08",{"date":60,"type":19},"2028-12-01",{"name":62,"class":43},"M.D. Anderson Cancer Center",1]